Novan SB206 Phase 3 Molluscum Pivotal Program Update

MORRISVILLE, N.C., July 11, 2019 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has exceeded 50 percent of expected patient enrollment in the Company’s ongoing “B-SIMPLE” (Berdazimer Sodium In Molluscum Patients with Lesions) Phase 3 pivotal trials.